Role of organ transplantation in the treatment of malignancies - Hepatocellular carcinoma as the most common tumour treated with transplantation

Gyula Végso, Dénes Görög, Imre Fehérvári, B. Nemes, Attila Doros, R. Langer, L. Kóbori

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

There are only few malignant tumours where organ transplantation is the treatment of choice. Transplantation can be considered individually in certain lung carcinomas, unresectable heart tumours, cholangiocellular carcinoma and Klatskin tumour. It is acceptable in unresectable chemosensitive hepatoblastoma, epitheloid haemangioendothelioma, liver metastasis of neuroendocrine tumours and as the most common indication, the early hepatocellular carcinoma (HCC) in cirrhotic liver. Results of liver transplantation (LT) for HCC according to Milan criteria as a "gold standard" are excellent. Time of LT has a great influence on the results. While patients are on waiting list, locoregional therapies may help prevent tumour progress. Living donor LT is an acceptable treatment of HCC. The greatest experience with this procedure is in Asia. Despite the favourable results, LT as the treatment of HCC is debated and raises several questions: regarding indication and expectable outcome. Milan criteria seem to answer this questions although they are too strict. The number and size of HCC foci per se is not sufficient predictor of eligibility to transplantation and for prognosis. Majority of the prognostic factors can be evaluated only after transplantation with pathological examination of HCC. Aim of the present research is to find prognostic factors that are characteristic of biological behaviour of HCC, which can be detected before LT in order to select patients who have the greatest benefit from LT. Re-definition of eligibility criteria is an actual question; an international consensus based on additional prospective studies is required for the "new" recommendation.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalPathology and Oncology Research
Volume18
Issue number1
DOIs
Publication statusPublished - Jan 2012

Fingerprint

Organ Transplantation
Hepatocellular Carcinoma
Liver Transplantation
Transplantation
Neoplasms
Therapeutics
Klatskin Tumor
Hemangioendothelioma
Hepatoblastoma
Heart Neoplasms
Waiting Lists
Neuroendocrine Tumors
Cholangiocarcinoma
Living Donors
Liver
Prospective Studies
Neoplasm Metastasis
Carcinoma
Lung
Research

Keywords

  • Bridging therapy
  • Bronchioloalveolar carcinoma
  • Des-gamma-carboxy prothrombin
  • Extended criteria
  • Heart sarcomas
  • Hepatocellular carcinoma
  • Liver transplantation
  • Living donor liver transplantation
  • Milan criteria
  • Proliferation signal inhibitor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

Role of organ transplantation in the treatment of malignancies - Hepatocellular carcinoma as the most common tumour treated with transplantation. / Végso, Gyula; Görög, Dénes; Fehérvári, Imre; Nemes, B.; Doros, Attila; Langer, R.; Kóbori, L.

In: Pathology and Oncology Research, Vol. 18, No. 1, 01.2012, p. 1-10.

Research output: Contribution to journalArticle

@article{0fdcf97e8ef24c2b9a8fe466f9d0b32f,
title = "Role of organ transplantation in the treatment of malignancies - Hepatocellular carcinoma as the most common tumour treated with transplantation",
abstract = "There are only few malignant tumours where organ transplantation is the treatment of choice. Transplantation can be considered individually in certain lung carcinomas, unresectable heart tumours, cholangiocellular carcinoma and Klatskin tumour. It is acceptable in unresectable chemosensitive hepatoblastoma, epitheloid haemangioendothelioma, liver metastasis of neuroendocrine tumours and as the most common indication, the early hepatocellular carcinoma (HCC) in cirrhotic liver. Results of liver transplantation (LT) for HCC according to Milan criteria as a {"}gold standard{"} are excellent. Time of LT has a great influence on the results. While patients are on waiting list, locoregional therapies may help prevent tumour progress. Living donor LT is an acceptable treatment of HCC. The greatest experience with this procedure is in Asia. Despite the favourable results, LT as the treatment of HCC is debated and raises several questions: regarding indication and expectable outcome. Milan criteria seem to answer this questions although they are too strict. The number and size of HCC foci per se is not sufficient predictor of eligibility to transplantation and for prognosis. Majority of the prognostic factors can be evaluated only after transplantation with pathological examination of HCC. Aim of the present research is to find prognostic factors that are characteristic of biological behaviour of HCC, which can be detected before LT in order to select patients who have the greatest benefit from LT. Re-definition of eligibility criteria is an actual question; an international consensus based on additional prospective studies is required for the {"}new{"} recommendation.",
keywords = "Bridging therapy, Bronchioloalveolar carcinoma, Des-gamma-carboxy prothrombin, Extended criteria, Heart sarcomas, Hepatocellular carcinoma, Liver transplantation, Living donor liver transplantation, Milan criteria, Proliferation signal inhibitor",
author = "Gyula V{\'e}gso and D{\'e}nes G{\"o}r{\"o}g and Imre Feh{\'e}rv{\'a}ri and B. Nemes and Attila Doros and R. Langer and L. K{\'o}bori",
year = "2012",
month = "1",
doi = "10.1007/s12253-011-9441-4",
language = "English",
volume = "18",
pages = "1--10",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Role of organ transplantation in the treatment of malignancies - Hepatocellular carcinoma as the most common tumour treated with transplantation

AU - Végso, Gyula

AU - Görög, Dénes

AU - Fehérvári, Imre

AU - Nemes, B.

AU - Doros, Attila

AU - Langer, R.

AU - Kóbori, L.

PY - 2012/1

Y1 - 2012/1

N2 - There are only few malignant tumours where organ transplantation is the treatment of choice. Transplantation can be considered individually in certain lung carcinomas, unresectable heart tumours, cholangiocellular carcinoma and Klatskin tumour. It is acceptable in unresectable chemosensitive hepatoblastoma, epitheloid haemangioendothelioma, liver metastasis of neuroendocrine tumours and as the most common indication, the early hepatocellular carcinoma (HCC) in cirrhotic liver. Results of liver transplantation (LT) for HCC according to Milan criteria as a "gold standard" are excellent. Time of LT has a great influence on the results. While patients are on waiting list, locoregional therapies may help prevent tumour progress. Living donor LT is an acceptable treatment of HCC. The greatest experience with this procedure is in Asia. Despite the favourable results, LT as the treatment of HCC is debated and raises several questions: regarding indication and expectable outcome. Milan criteria seem to answer this questions although they are too strict. The number and size of HCC foci per se is not sufficient predictor of eligibility to transplantation and for prognosis. Majority of the prognostic factors can be evaluated only after transplantation with pathological examination of HCC. Aim of the present research is to find prognostic factors that are characteristic of biological behaviour of HCC, which can be detected before LT in order to select patients who have the greatest benefit from LT. Re-definition of eligibility criteria is an actual question; an international consensus based on additional prospective studies is required for the "new" recommendation.

AB - There are only few malignant tumours where organ transplantation is the treatment of choice. Transplantation can be considered individually in certain lung carcinomas, unresectable heart tumours, cholangiocellular carcinoma and Klatskin tumour. It is acceptable in unresectable chemosensitive hepatoblastoma, epitheloid haemangioendothelioma, liver metastasis of neuroendocrine tumours and as the most common indication, the early hepatocellular carcinoma (HCC) in cirrhotic liver. Results of liver transplantation (LT) for HCC according to Milan criteria as a "gold standard" are excellent. Time of LT has a great influence on the results. While patients are on waiting list, locoregional therapies may help prevent tumour progress. Living donor LT is an acceptable treatment of HCC. The greatest experience with this procedure is in Asia. Despite the favourable results, LT as the treatment of HCC is debated and raises several questions: regarding indication and expectable outcome. Milan criteria seem to answer this questions although they are too strict. The number and size of HCC foci per se is not sufficient predictor of eligibility to transplantation and for prognosis. Majority of the prognostic factors can be evaluated only after transplantation with pathological examination of HCC. Aim of the present research is to find prognostic factors that are characteristic of biological behaviour of HCC, which can be detected before LT in order to select patients who have the greatest benefit from LT. Re-definition of eligibility criteria is an actual question; an international consensus based on additional prospective studies is required for the "new" recommendation.

KW - Bridging therapy

KW - Bronchioloalveolar carcinoma

KW - Des-gamma-carboxy prothrombin

KW - Extended criteria

KW - Heart sarcomas

KW - Hepatocellular carcinoma

KW - Liver transplantation

KW - Living donor liver transplantation

KW - Milan criteria

KW - Proliferation signal inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84855254546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855254546&partnerID=8YFLogxK

U2 - 10.1007/s12253-011-9441-4

DO - 10.1007/s12253-011-9441-4

M3 - Article

VL - 18

SP - 1

EP - 10

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 1

ER -